Declaration obligation of the insurant during the conclusion of the contract
2021
2 views
1 downloads
Advisor: Dr. Öğr. Üyesi Zuhal Arıç
Abstract (EN)
In order to achieve a balance between the parties obligations under insurance contracts, the duty of disclosure required by the general duty to act in goodfaith must be complied with. The duty of disclosure in the pre-contractual stageis a reflection of the duty of goodfaith. It is essential that the policyholder behaves in an acceptable and bona fide manner during negotiations leading to the signing of a contract, otherwise the policyholder will forfeit the contractual rights due to a breach of the duty of disclosure. In this study, the policyholder sduty of pre-contractual disclosure, the purpose there of, the facts needed to be disclosed there under, the method of disclosure and the consequences of a breachare examined. The approaches adopted by the Supreme Court of Appeals concerning the policyholder sduty of disclosure are critised, along with the way the issues are governed by the Turkish Commercial Code. Furthermore, the regulations relevant to the duty under German Law are discussed in this study.
Author
Hüsna Yıldırım Yaraşıklı
Institution
How to Cite
Hüsna Yıldırım Yaraşıklı (Master Thesis). Declaration obligation of the insurant during the conclusion of the contract, 2021, Yeditepe University.
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Yeditepe University
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)